PharVision Advisers’s Loews L Stock Holding History

PharVision Advisers’s Portfolio L Stock Details L Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,326	Closed	-$245K	–	394
2025 Q4	$245K	Buy	+2,326	New	+$240K	0.12%	407

Other funds holding L

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PharVision Advisers's L Position: Q1 2026 in Review

PharVision Advisers sold out of Loews (L) in Q1 2026, closing a stake of 2,326 shares — an estimated $245K sold.

PharVision Advisers first reported a position in L in Q4 2025 and held it in 1 quarter. The position peaked at $245K in Q4 2025. 769 funds tracked by Wall St. Rank hold L as of Q1 2026.

PharVision Advisers reported no remaining Loews position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 2,326 Loews shares in Q1 2026, an estimated $245K.
PharVision Advisers first reported a position in Loews in Q4 2025 and held it in 1 quarter.
PharVision Advisers's Loews position peaked at $245K in Q4 2025.
769 funds tracked by Wall St. Rank held Loews as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.